353 related articles for article (PubMed ID: 32119788)
1. Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
Mak JWY; So J; Tang W; Yip TCF; Leung WK; Li M; Lo FH; Ng KM; Sze SF; Leung CM; Tsang SWC; Shan EHS; Chan KH; Lam BCY; Hui AJ; Chow WH; Chan FKL; Ng SC
Scand J Gastroenterol; 2020 Mar; 55(3):279-286. PubMed ID: 32119788
[No Abstract] [Full Text] [Related]
2. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Bernstein CN; Nugent Z; Blanchard JF
Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
[TBL] [Abstract][Full Text] [Related]
3. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.
van Staa TP; Card T; Logan RF; Leufkens HG
Gut; 2005 Nov; 54(11):1573-8. PubMed ID: 15994215
[TBL] [Abstract][Full Text] [Related]
4. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
[TBL] [Abstract][Full Text] [Related]
5. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.
van Schaik FD; van Oijen MG; Smeets HM; van der Heijden GJ; Siersema PD; Oldenburg B
Gut; 2012 Feb; 61(2):235-40. PubMed ID: 21602529
[TBL] [Abstract][Full Text] [Related]
6. [Inflammatory bowel disease and colorectal cancer].
Hagymási K; Tulassay Z
Orv Hetil; 2006 Oct; 147(41):1977-82. PubMed ID: 17120688
[TBL] [Abstract][Full Text] [Related]
7. Mesalamine protects against colorectal cancer in inflammatory bowel disease.
Tang J; Sharif O; Pai C; Silverman AL
Dig Dis Sci; 2010 Jun; 55(6):1696-703. PubMed ID: 19705280
[TBL] [Abstract][Full Text] [Related]
8. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
9. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use.
Samadder NJ; Mukherjee B; Huang SC; Ahn J; Rennert HS; Greenson JK; Rennert G; Gruber SB
Cancer; 2011 Apr; 117(8):1640-8. PubMed ID: 21472711
[TBL] [Abstract][Full Text] [Related]
10. Increased risk of pneumonia among patients with inflammatory bowel disease.
Long MD; Martin C; Sandler RS; Kappelman MD
Am J Gastroenterol; 2013 Feb; 108(2):240-8. PubMed ID: 23295276
[TBL] [Abstract][Full Text] [Related]
11. [Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases].
Ioffe AIu
Lik Sprava; 2005 Jun; (4):45-8. PubMed ID: 16158715
[TBL] [Abstract][Full Text] [Related]
12. Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study.
Crockett SD; Hansen RA; Stürmer T; Schectman R; Darter J; Sandler RS; Kappelman MD
Inflamm Bowel Dis; 2012 Jun; 18(6):1048-56. PubMed ID: 21826766
[TBL] [Abstract][Full Text] [Related]
13. Colorectal cancer in inflammatory bowel diseases: a population-based study (1976-2008).
Peyrin-Biroulet L; Lepage C; Jooste V; Guéant JL; Faivre J; Bouvier AM
Inflamm Bowel Dis; 2012 Dec; 18(12):2247-51. PubMed ID: 22467511
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease.
Pearce CB; Duncan HD; Timmis L; Green JR
Eur J Gastroenterol Hepatol; 2000 Apr; 12(4):439-43. PubMed ID: 10783998
[TBL] [Abstract][Full Text] [Related]
15. [Colorectal cancer in inflammatory bowel disease].
Henriksen M; Moum B
Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2696-9. PubMed ID: 17952155
[TBL] [Abstract][Full Text] [Related]
16. Mesalazine in inflammatory bowel disease: a trendy topic once again?
Iacucci M; de Silva S; Ghosh S
Can J Gastroenterol; 2010 Feb; 24(2):127-33. PubMed ID: 20151072
[TBL] [Abstract][Full Text] [Related]
17. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH
Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187
[TBL] [Abstract][Full Text] [Related]
18. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Klotz U
Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
[TBL] [Abstract][Full Text] [Related]
19. 5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease.
Cheng Y; Desreumaux P
World J Gastroenterol; 2005 Jan; 11(3):309-14. PubMed ID: 15637733
[TBL] [Abstract][Full Text] [Related]
20. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
